For the second quarter of the fiscal year ending June 2026, net sales were JPY 109,261 million (10.6% YoY increase), operating income was JPY 5,717 million (24.4% YoY increase), and net income attributable to owners of parent was JPY 4,020 million (23.0% YoY increase).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"9267","jir_company_name":"Genky DrugStores Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-01-27","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/01\/9267-20260127-02.pdf","jir_short_summary":"For the second quarter of the fiscal year ending June 2026, net sales were JPY 109,261 million (10.6% YoY increase), operating income was JPY 5,717 million (24.4% YoY increase), and net income attributable to owners of parent was JPY 4,020 million (23.0% YoY increase).","jir_summary":"### Overview of Performance\nFor the second quarter of the fiscal year ending June 2026 (June 21, 2025 to December 20, 2025), consolidated net sales amounted to JPY 109,261 million, representing a 10.6% increase year-over-year. Operating income was JPY 5,717 million (24.4% increase YoY), ordinary income was JPY 5,843 million (23.7% increase YoY), and net income attributable to owners of parent was JPY 4,020 million (23.0% increase YoY). The number of stores totaled 499 (466 regular stores and 33 large-scale stores), with new openings and refurbishments carried out. By product category, food accounted for the largest sales, followed by sundries, cosmetics, and pharmaceuticals.\n\n### Overview of Financial Condition and Dividend\nTotal assets increased by JPY 7,094 million from the end of the previous consolidated fiscal year to JPY 134,420 million. Net assets rose by JPY 4,216 million to JPY 57,644 million, and the equity ratio stood at 42.8%, indicating a solid financial foundation. Cash flows from operating activities generated JPY 7,461 million, while expenditures on investing activities amounted to JPY 9,814 million. The year-end dividend is planned at JPY 6.50 per share, with an annual dividend forecast of JPY 13.00, unchanged from the previous term. The full-year earnings forecast for FY June 2026 anticipates net sales of JPY 221,200 million, operating income of JPY 11,050 million, and net income of JPY 7,850 million, expecting increases in revenue and earnings.","jir_financial_highlights":"Net Sales: JPY 109,261 million (10.6% Year-over-Year increase)\nOperating Income: JPY 5,717 million (24.4% Year-over-Year increase)\nOrdinary Income: JPY 5,843 million (23.7% Year-over-Year increase)\nNet Income Attributable to Owners of Parent: JPY 4,020 million (23.0% Year-over-Year increase)\nInterim Net Income per Share: JPY 132.12 (Increase from JPY 107.55 for the same period last year)\nTotal Assets: JPY 134,420 million (Increase of JPY 7,094 million from the end of the previous consolidated fiscal year)\nNet Assets: JPY 57,644 million (Increase of JPY 4,216 million from the end of the previous consolidated fiscal year)\nEquity Ratio: 42.8% (Increase from 41.8% at the end of the previous consolidated fiscal year)\nAnnual Dividend (Forecast): JPY 13.00 (No change)\nFull-Year Earnings Guidance for FY June 2026 Net Sales: JPY 221,200 million (10.2% Increase over previous fiscal year)\nFull-Year Earnings Guidance for FY June 2026 Operating Income: JPY 11,050 million (14.4% Increase over previous fiscal year)\nFull-Year Earnings Guidance for FY June 2026 Net Income Attributable to Owners of Parent: JPY 7,850 million (11.1% Increase over previous fiscal year)","jir_category":"","jir_hashtags":"#GenkyDrugStores, #FinancialSummary, #JapaneseStocks","jir_key_figures":"Net Sales: JPY 109,261 million (10.6% Year-over-Year increase)\nOperating Income: JPY 5,717 million (24.4% Year-over-Year increase)\nNet Income Attributable to Owners of Parent: JPY 4,020 million (23.0% Year-over-Year increase)","jir_meta_title":"Genky DrugStores 2Q FY2026 Financial Results - Net Sales Up 10.6%, Operating Income Up 24.4%","jir_meta_description":"Genky DrugStores Co., Ltd. announces its financial summary for the second quarter of FY ending June 2026. Net sales reached JPY 109,261 million (10.6% YoY increase), operating income JPY 5,717 million (24.4% YoY increase), and net income JPY 4,020 million (23.0% YoY increase), recording growth in revenue and profits. Annual dividend forecast is JPY 13.00.","jir_og_title":"Genky DrugStores Announces 2Q FY2026 Financial Results - Net Sales Up 10.6%","jir_og_description":"Second quarter financial summary for FY June 2026: net sales of JPY 109,261 million, operating income of JPY 5,717 million, and net income of JPY 4,020 million, marking significant year-over-year growth.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Sales Trend (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"1H FY2025\\\",\\\"1H FY2026\\\",\\\"FY2025 Forecast\\\",\\\"FY2026 Forecast\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[98758,109261,200000,221200],\\\"backgroundColor\\\":\\\"#4e79a7\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Operating Income Trend (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"1H FY2025\\\",\\\"1H FY2026\\\",\\\"FY2025 Forecast\\\",\\\"FY2026 Forecast\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[4596,5717,9650,11050],\\\"backgroundColor\\\":\\\"#f28e2b\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent Trend (Million JPY)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"1H FY2025\\\",\\\"1H FY2026\\\",\\\"FY2025 Forecast\\\",\\\"FY2026 Forecast\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[3268,4020,7050,7850],\\\"backgroundColor\\\":\\\"#e15759\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":9174,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-21035","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n